Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ter Arkh ; 93(12): 1510-1515, 2021 Dec 15.
Artigo em Russo | MEDLINE | ID: mdl-36286680

RESUMO

AIM: To assess the influence of the therapy of arterial hypertension with azilsartan medoxomil on the renal function in overweight or obese patients with concomitant metabolic disorders. MATERIALS AND METHODS: An international multicenter observational nonintervention prospective study included 1945 patients, taking azilsartan medoxomil in accordance with approved prescribing information. The observation period reached 6 months. RESULTS: In patients with an initial glomerular filtration rate (GFR)60 ml/min/1.73 m2 or 60 ml/min/1.73 m2 mean change in systolic blood pressure after 6 months of therapy reached -32.511.1 and -30.413.6 mmHg, correspondingly, while the change in diastolic blood pressure was -13.78.8 and -14.29.4 mmHg, respectively. No decrease in renal function was observed. Moreover, in patients with an initial GFR60 ml/min/1.73 m2 GFR increased significantly (p0.001). CONCLUSION: Azilsartan medoxomil, prescribed as monotherapy or in free combinations, provided an effective control of blood pressure in patients with arterial hypertension with both normal or moderately reduced and initially significantly reduced renal function. High efficacy and acceptability of the drug was associated with a beneficial effect on renal function, which allows to consider azilsartan medoxomil as the drug of choice for the treatment of hypertension in patients with concomitant metabolic disorders.


Assuntos
Hipertensão , Doenças Metabólicas , Humanos , Anti-Hipertensivos/efeitos adversos , Sobrepeso/complicações , Sobrepeso/tratamento farmacológico , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Estudos Prospectivos , Hipertensão/complicações , Hipertensão/diagnóstico , Hipertensão/tratamento farmacológico , Pressão Sanguínea , Obesidade/complicações , Obesidade/tratamento farmacológico , Rim/fisiologia , Doenças Metabólicas/tratamento farmacológico , Tetrazóis/farmacologia , Tetrazóis/uso terapêutico , Resultado do Tratamento
2.
Ter Arkh ; 78(5): 65-8, 2006.
Artigo em Russo | MEDLINE | ID: mdl-16889053

RESUMO

AIM: To assess antihypertensive efficacy of a low-dose combination of amlodipin with lisinopril in the treatment of patients with arterial hypertension (AH) of the second degree. MATERIAL AND METHODS: A total of 42 patients with the second degree of AH (16 males, 26 females, mean age 55-9 +/- 1.9 years) entered an open, comparative and controlled trial. They were divided into three groups by the treatment. Group 1 (n = 14) received amlodipin (normodipin, Gedeon Richter) monotherapy in a mean dose 8.9 +/- 0.6 mg/day, group 2 (n = 12) - lisinopril (diroton, Gedeon Richter) in a mean dose 17.5 +/- 1.4 mg/day, group 3 (n = 16) was given combined therapy with amlodipin+lisinopril in a dose 6.8 +/- 0.7 and 8.7 +/- 0.6 mg/day, respectively. The drugs were given for 12 weeks. The efficacy of the treatment was assessed by the results of 24-h monitoring of blood pressure, echocardiography, endothelium-related vasodilatation of the brachial artery (ERVD), dopplerographic investigation of circulation in the middle cerebral artery (MCA), heart rate and cost-effect estimation. RESULTS: Combined low-dose treatment with amlodipin and lisinopril for 12 weeks allowed achievement of target blood pressure in more patients and lower systolic and diastolic blood pressure than monotherapy with each of the drugs. There was also a positive effect on E/A index, ERVD, MCA circulation. CONCLUSION: Low-dose combined treatment with lisinopril and amlodipin is more effective and cost-efficient. Moreover, lisinopril addition to amlodipin corrects side effects of amlodipin on central nervous system.


Assuntos
Anlodipino/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Bloqueadores dos Canais de Cálcio/uso terapêutico , Hipertensão/tratamento farmacológico , Lisinopril/uso terapêutico , Anlodipino/economia , Inibidores da Enzima Conversora de Angiotensina/economia , Bloqueadores dos Canais de Cálcio/economia , Análise Custo-Benefício , Esquema de Medicação , Quimioterapia Combinada , Ecocardiografia , Feminino , Humanos , Hipertensão/diagnóstico por imagem , Hipertensão/economia , Lisinopril/economia , Masculino , Pessoa de Meia-Idade , Ultrassonografia Doppler
3.
Ter Arkh ; 75(10): 50-4, 2003.
Artigo em Russo | MEDLINE | ID: mdl-14669607

RESUMO

AIM: To study endothelium-dependent vasodilatation (EDVD), plasma endothelin 1,2 (ET-1,2) contents and urinary NO metabolites in normal pregnancy and various kinds of gestoses with evaluation of normodipine effects on blood pressure and EDVD. MATERIAL AND METHODS: 59 primigravidas 18-32 years of age (pregnancy terms 34-39 weeks) were divided into three groups. Group 1 consisted of 23 women with arterial hypertension treated with normodipine in 11 of them. In group 2 sixteen pregnant women had edema and group 3 consisted of 20 women with physiological pregnancy. 12 non-pregnant women comprised a control group. RESULTS: In normal pregnancy ET-1,2 content was low while urine NO metabolites levels were high. This contributes to maintaining adequate reaction of the brachial artery in response to the "shiftstress". In women with edema the brachial artery response to short-term occlusion was decreased. In women with both high blood pressure and edema had vascular response paradoxically spastic with a two-fold decrease in blood flow rate, high plasma ET-1.2 contents and low urine NO metabolites levels. Normodipine in gestational arterial hypertension normalizes both blood pressure and EDVD. CONCLUSION: Endothelial dysfunction is an important factor predisposing to development of arterial hypertension. Monotherapy with normodipine (5 mg/day in a single daily dose) during 3 weeks is effective in controlling gestational hypertension.


Assuntos
Anlodipino/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Hipertensão/tratamento farmacológico , Complicações Cardiovasculares na Gravidez/tratamento farmacológico , Vasodilatação/efeitos dos fármacos , Adolescente , Adulto , Braço/irrigação sanguínea , Artérias/efeitos dos fármacos , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Endotelina-1/sangue , Endotelina-2/sangue , Endotélio Vascular/efeitos dos fármacos , Feminino , Humanos , Hipertensão/metabolismo , Hipertensão/fisiopatologia , Nitratos/urina , Nitritos/urina , Gravidez , Complicações Cardiovasculares na Gravidez/metabolismo , Complicações Cardiovasculares na Gravidez/fisiopatologia , Terceiro Trimestre da Gravidez , Resultado do Tratamento
4.
Vopr Pitan ; 72(4): 29-32, 2003.
Artigo em Russo | MEDLINE | ID: mdl-12968301

RESUMO

The aim of the present study is to evaluate the alimentary disorders in patients with high risk for cardiovascular diseases, also in patients with arterial hypertension (AH) and njn--insulin-diabetes mellitus (DM). The results showed that patients with AH (155 patients) and DM (107 patients) have high prevalence of the alimentary disorders: high consumption of total fat--46% (DM) and 70.9% (AH), high consumption of carbohydrates--14.9% and 73%, salt intake--34.9% and 68.6%, respectively. Application of special training programs in groups provided stable modification of dietary habits and was more effective, compared with the traditional ones. These groups demonstrated better results in dietary habits modification, compared with the existing routine individual medical control groups.


Assuntos
Diabetes Mellitus Tipo 2/psicologia , Comportamento Alimentar , Hipertensão/psicologia , Educação de Pacientes como Assunto/métodos , Adulto , Terapia Comportamental/métodos , Doenças Cardiovasculares/prevenção & controle , Humanos , Pessoa de Meia-Idade , Distúrbios Nutricionais/psicologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...